Elahere (mirvetuximab soravtansine) is neither traditional chemotherapy nor immunotherapy. It belongs to a newer category called antibody-drug conjugates, or ADCs, which combine elements of both approaches. The drug pairs a targeted antibody with a potent cell-killing chemical payload, delivering chemotherapy-like destruction specifically to cancer cells while largely sparing healthy tissue.
What an Antibody-Drug Conjugate Actually Is
An ADC is essentially a guided missile. It has three parts: an antibody that recognizes a specific protein on cancer cells, a chemical linker that holds everything together, and a cytotoxic (cell-killing) payload that does the actual damage. In Elahere’s case, the antibody locks onto a protein called folate receptor alpha (FRα), which is found at high levels on certain ovarian cancer cells. Once the antibody attaches, the entire drug is pulled inside the cancer cell. The linker then breaks apart, releasing the toxic payload directly where it can do its work.
The payload in Elahere is a compound called DM4, which belongs to a family of potent cell-killing agents known as maytansinoids. DM4 destroys the internal scaffolding that cells need to divide. Without that scaffolding (called microtubules), the cancer cell can’t complete division and dies. This mechanism is similar to how some traditional chemotherapy drugs work, but the key difference is delivery: instead of flooding the entire body with a toxic drug, the antibody carries it directly to cells displaying the FRα target.
How It Differs From Traditional Chemotherapy
Standard chemotherapy drugs circulate throughout the body and attack any rapidly dividing cell, cancerous or not. That’s why conventional chemo causes widespread side effects like hair loss, nausea, and immune suppression: the drugs can’t distinguish between a cancer cell and a healthy cell that happens to be dividing quickly.
ADCs like Elahere are designed to be more selective. The antibody component acts as a homing device, directing the toxic payload primarily to cancer cells that express the target protein. Normal cells that lack FRα on their surface are largely left alone. This precision means the drug can use an extremely potent payload, one that would be far too toxic to give on its own as traditional chemotherapy, while reducing collateral damage to healthy tissue.
Elahere also has what researchers call a “bystander effect.” Once the DM4 payload is released inside a targeted cancer cell, some of those toxic molecules can diffuse into neighboring cancer cells. This is particularly useful when a tumor has uneven levels of FRα expression, because even cancer cells with lower amounts of the target protein can still be affected.
How It Differs From Immunotherapy
Immunotherapy works by activating or enhancing your own immune system to recognize and attack cancer. Checkpoint inhibitors, for example, remove the “brakes” that cancer cells use to hide from immune detection. CAR-T cell therapy engineers your immune cells to hunt down cancer. These approaches rely on the body’s immune response to do the killing.
Elahere does use an antibody, which is a tool borrowed from immune system biology. But it doesn’t recruit or activate your immune system to fight the cancer. The antibody’s role is purely navigational: find the target, deliver the payload. The cancer cell dies from the chemical payload, not from an immune response. That’s why the FDA and the National Comprehensive Cancer Network classify Elahere as an ADC and a targeted therapy, not as immunotherapy.
Who Elahere Is Approved For
Elahere is FDA-approved for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer that tests positive for FRα. “Platinum-resistant” means the cancer came back within a relatively short time after platinum-based chemotherapy, a standard first-line treatment for ovarian cancer. Patients must have received one to three prior treatment regimens to be eligible.
Before starting Elahere, your tumor must be tested with an FDA-approved diagnostic to confirm it has high levels of FRα. Not all ovarian cancers express this protein at levels high enough for the drug to work effectively, so this testing step is required. The NCCN guidelines list Elahere as a preferred option specifically for recurrent ovarian cancer with high FRα expression.
What Treatment Looks Like
Elahere is given as an intravenous infusion once every three weeks. During your first infusion, the rate starts slowly and is gradually increased over the course of the session if you tolerate it well. The initial rate is held for 30 minutes, then doubled, held again, and potentially increased further up to a maximum speed. If you don’t have any infusion-related reactions during your first treatment, subsequent sessions can start at the faster rate right away.
Treatment continues on this three-week cycle until the cancer progresses or the side effects become unmanageable. Because Elahere targets a protein found not just on cancer cells but also on some cells in the eye, vision-related side effects are a known concern. Your care team will likely schedule regular eye exams throughout treatment to monitor for any changes. Other side effects can include fatigue, nausea, and changes in blood counts, though the targeted delivery generally means less severe systemic toxicity compared to conventional chemotherapy.
Why the Distinction Matters
Understanding that Elahere is an ADC rather than pure chemotherapy or immunotherapy helps set realistic expectations. You won’t experience the same broad-spectrum side effect profile as traditional chemo, but you also won’t see the durable immune-mediated responses that some immunotherapy patients achieve. ADCs occupy a middle ground: highly targeted, chemically potent, and dependent on the tumor expressing the right surface protein.
If your oncologist has recommended Elahere, the most important practical takeaway is the FRα testing requirement. The drug only works when the cancer displays enough of its target protein. A negative or low-expression test result means Elahere isn’t likely to be effective for your particular cancer, regardless of the diagnosis.